Pfizer/BioNTech's COVID-19 vaccine is 90% effective

from Phase III clinical trials, a potential COVID-19 vaccine developed by U.S. pharmaceutical giant Pfizer Inc. and Germany-based BioNTech Inc. has a 90 percent effective rate, according to early data from Phase III clinical trials.Pfizer and BioNTech's Phase III trial of the COVID-19 vaccine candidate BNT162b2 involved 43,538 people who received two doses of the vaccine or placebo.In today's announcement, Pfizer and BioNTech said their vaccines are more than 90 percent effective seven days after receiving a second dose. In the trial, 94 participants developed the new coronavirus SARS-CoV-2, which can cause COVID-19. The trial is continuing to recruit participants and will be finally analysed in a total of 164 COVID-19 cases.The companies added that they are collecting security data, which is now estimated to be available in the third week of November, two months after the second vaccination.Pfizer and BioNTech also plan to submit complete Phase III data for scientific peer review and publication."Today is a great day for science and the humanities," said Albert Burra, Pfizer's chairman and chief executive. The first results from our Phase III COVID-19 vaccine trial provide preliminary evidence of the vaccine's ability to prevent COVID-19. The final analysis will also include a new secondary endpoint, i.e. an assessment of vaccine effectiveness based on cases generated after 14 days of the second dose. Thehope that the addition of these new secondary endpoints will help "adjust" data from all new coronary pneumonia vaccine studies to enable cross-test learning and comparison between new vaccine platforms. Uur Sahin, Co-Founder and CEO of BioNTech, said, "When we started this journey ten months ago, that's what we wanted to achieve. Especially today, while we are all in the second wave and many of us are under blockade, we appreciate even more how important this milestone is on the road to ending this pandemic and regaining a sense of normality for all of us. (cyy123.com)original title: early data directory Pfizer/BioNTech's COVID-19 vaccine is 90%